U.S. pharma giant copyright scrapped two experimental weight loss tablets past calendar year—a as soon as-day by day tablet, lotiglipron, as a result of elevated liver enzymes plus a 2 times-everyday capsule, danuglipron, as a consequence of robust Unwanted side effects—but CEO Albert Bourla has said the company is decided to “Participate in